Drug Trial Radar · NCT01609062
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
Last checked: Nov 20, 2026Latest source record: Feb 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
25
Actual
Start
Apr 2012
Primary completion
Nov 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- May 31, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.
Conditions
- Mucopolysaccharidosis IVA
- Morquio A Syndrome
- MPS IVA
Interventions
BMN 110Drug
Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
BMN 110Drug
Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationTime frame: Entire Study Period, up to 192 weeks or ETV (early termination visit)
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Oakland, California
Site not named
Chicago, Illinois
Site not named
New York, New York
Site not named
Houston, Texas
Site not named
Calgary, Alberta, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Sherbrook, Quebec, Canada
Site not named
Hamburg, Germany
Site not named
Manchester, United Kingdom
Site not named
Belfast, Northern Ireland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.